Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.59)
# 205
Out of 5,172 analysts
141
Total ratings
49.61%
Success rate
41.3%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $22 | $6.63 | +231.83% | 3 | Mar 18, 2026 | |
| TBPH Theravance Biopharma | Downgrades: Neutral | $28 → $14 | $14.33 | -2.30% | 2 | Mar 4, 2026 | |
| NKTR Nektar Therapeutics | Reiterates: Buy | $105 → $150 | $72.22 | +107.70% | 4 | Feb 23, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $90 → $108 | $61.70 | +75.04% | 6 | Jan 21, 2026 | |
| IRD Opus Genetics | Initiates: Buy | $9 | $4.39 | +105.01% | 1 | Dec 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $27.06 | +55.24% | 2 | Dec 1, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $30 → $40 | $23.32 | +71.53% | 2 | Nov 21, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $12 | $4.22 | +184.36% | 1 | Nov 19, 2025 | |
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $9.62 | +66.32% | 20 | Nov 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $33.28 | +122.36% | 4 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $560 | $441.16 | +26.94% | 13 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $30.07 | +82.91% | 14 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.35 | +751.06% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $3.34 | +438.92% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.56 | +220.51% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $2.86 | +4.90% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.63 | +216.96% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $10.61 | +88.50% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.45 | +106.90% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $20.17 | +73.53% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $56.33 | -32.54% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $32.33 | +196.94% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.07 | +40.19% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $7.52 | +1,761.70% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $4.28 | +2,002.80% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.71 | +4,212.67% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.95 | +156.41% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.99 | +2,910.03% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.17 | +498.29% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $0.85 | +530,810.81% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.20 | +224,900.00% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $0.60 | +239,900.00% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $2.75 | +45.45% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $81.42 | -52.10% | 2 | Mar 18, 2020 |
Arcturus Therapeutics Holdings
Mar 18, 2026
Initiates: Buy
Price Target: $22
Current: $6.63
Upside: +231.83%
Theravance Biopharma
Mar 4, 2026
Downgrades: Neutral
Price Target: $28 → $14
Current: $14.33
Upside: -2.30%
Nektar Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $105 → $150
Current: $72.22
Upside: +107.70%
Cytokinetics
Jan 21, 2026
Maintains: Buy
Price Target: $90 → $108
Current: $61.70
Upside: +75.04%
Opus Genetics
Dec 10, 2025
Initiates: Buy
Price Target: $9
Current: $4.39
Upside: +105.01%
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $27.06
Upside: +55.24%
Zymeworks
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $23.32
Upside: +71.53%
Nuvation Bio
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $4.22
Upside: +184.36%
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $9.62
Upside: +66.32%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $33.28
Upside: +122.36%
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $441.16
Upside: +26.94%
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $30.07
Upside: +82.91%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $2.35
Upside: +751.06%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $3.34
Upside: +438.92%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.56
Upside: +220.51%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $2.86
Upside: +4.90%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.63
Upside: +216.96%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $10.61
Upside: +88.50%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.45
Upside: +106.90%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $20.17
Upside: +73.53%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $56.33
Upside: -32.54%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $32.33
Upside: +196.94%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.07
Upside: +40.19%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $7.52
Upside: +1,761.70%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $4.28
Upside: +2,002.80%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.71
Upside: +4,212.67%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.95
Upside: +156.41%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.99
Upside: +2,910.03%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.17
Upside: +498.29%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $0.85
Upside: +530,810.81%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.20
Upside: +224,900.00%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $0.60
Upside: +239,900.00%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $2.75
Upside: +45.45%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $81.42
Upside: -52.10%